Chinook Starts Pivotal Phase 3 Study of Zigakibart (BION-1301) for IgA Nephropathy

 Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.

https://www.biospace.com/article/releases/chinook-therapeutics-announces-first-patient-enrolled-in-pivotal-phase-3-beyond-study-of-zigakibart-bion-1301-for-patients-with-iga-nephropathy/